INO
Inovio Pharmaceuticals Inc
NASDAQ: INO · HEALTHCARE · BIOTECHNOLOGY
$1.12
+0.00% today
Updated 2026-04-30
Market cap
$95.46M
P/E ratio
—
P/S ratio
1,460.95x
EPS (TTM)
$-1.81
Dividend yield
—
52W range
$1 – $3
Volume
1.8M
Inovio Pharmaceuticals Inc (INO) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-132,871.00%
ROE
-183.50%
ROA
-57.90%
Debt/equity
-1.30x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $3.47M | $-12.48M | 93.51% | -384.82% | -359.82% |
| 2007 | $4.81M | $-11.20M | 100.00% | -330.68% | -233.05% |
| 2008 | $2.10M | $-12.97M | 100.00% | -651.14% | -618.11% |
| 2009 | $9.12M | $-24.41M | 100.00% | -153.04% | -267.67% |
| 2010 | $6.14M | $-17.61M | 100.00% | -312.79% | -286.65% |
| 2011 | $9.80M | $-15.25M | 100.00% | -220.91% | -155.72% |
| 2012 | $4.12M | $-19.67M | 100.00% | -570.42% | -477.56% |
| 2013 | $13.47M | $-66.03M | 100.00% | -145.12% | -490.29% |
| 2014 | $10.46M | $-36.12M | 100.00% | -377.71% | -345.44% |
| 2015 | $40.57M | $-29.19M | 100.00% | -84.50% | -71.94% |
| 2016 | $35.37M | $-73.74M | 100.00% | -215.55% | -208.49% |
| 2017 | $42.22M | $-88.21M | 100.00% | -198.11% | -208.92% |
| 2018 | $30.48M | $-96.97M | 100.00% | -308.68% | -318.12% |
| 2019 | $4.11M | $-119.36M | 100.00% | -2,702.10% | -2,902.75% |
| 2020 | $7.41M | $-166.41M | 100.00% | -1,674.25% | -2,245.39% |
| 2021 | $1.77M | $-303.66M | 100.00% | -16,972.34% | -17,109.87% |
| 2022 | $10.26M | $-279.82M | 100.00% | -2,607.35% | -2,726.67% |
| 2023 | $832010.00 | $-135.12M | 100.00% | -17,300.28% | -16,239.87% |
| 2024 | $217756.00 | $-107.25M | -1,337.41% | -51,616.91% | -49,254.27% |
| 2025 | $65343.00 | $-84.95M | 100.00% | -132,871.32% | -130,000.00% |